58O Real-world overall survival (OS) with durvalumab (D) after chemoradiotherapy (CRT) in patients (pts) with unresectable stage III non-small cell lung cancer (NSCLC): Interim analysis from the PACIFIC-R study

N. Girard, D.C.C. Christoph,M.C. Garassino,F. McDonald,F. Mornex,J.K. Field,R. Fietkau,P. Garrido Lopez,V.D. Haakensen,S. Siva,M. van den Heuvel,J. Bar,C. Chouaid, P. Vercauter,P. Chander,M. Licour, S. Anand, A.R.M.D. de Lima,A.R.R. Filippi

Immuno-Oncology and Technology（2022）

Cited 1|Views9

No score

Abstract

Following the PACIFIC trial, consolidation D for up to 12 months became a global SoC for pts with unresectable Stage III NSCLC and no disease progression after platinum-based CRT. We report the first planned analysis of OS from PACIFIC-R (NCT03798535), an international study assessing the effectiveness of D in pts from an early access programme (EAP).

Translated text

Key words

lung cancer,cell lung cancer,durvalumab,chemoradiotherapy,real-world,non-small

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined